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ABSTRACT
Purpose To compare physiochemical properties of mono-, di-
and triglycerides of medium chain fatty acids for development of
oral pharmaceutical dosage forms of poorly water-soluble drugs
using phase diagrams, drug solubility, and drug dispersion
experiments.
Methods Phasediagramswerepreparedusingamonoglyceride
(glycerolmonocaprylocaprate:CapmulMCM®EP),adiglyceride
(glycerol dicaprylate) and two triglycerides (glycerol tricaprylate:
Captex 8000®; caprylic/capric triglycerides: Captex 355 EP/NF®)
in combination with a common surfactant (PEG-35 castor oil:
Cremophor EL®) and water. Psuedoternary phase diagrams using
mixtures of monoglyceride with either diglyceride or triglyceride
were constructed to determine any potential advantage of using
lipid mixtures.
Result The monoglyceride gave microemulsion (clear or
translucent liquid) and emulsion phases, whereas di- and
triglycerides exhibited an additional gel phase. Among individual
mono-, di- and triglycerides, the oil-in-water microemulsion
region was the largest for the diglyceride. Gel phase region
within diglyceride and triglyceride phase diagrams could be
practically eliminated and microemulsion regions expanded by
mixing monoglyceride with di- or tri-glycerides (1:1). Addition
of a model drug, danazol, had no effect on particle sizes of
microemulsions formed. Dispersion of drug in aqueous media
from mixtures of mono- and diglyceride or mono- and
triglyceride was superior to individual lipids.
Conclusion Systematic study on comparison of mono-, di-
and triglyceride of medium chain fatty acids will help
formulators select components for optimal lipid-based formu-
lation.
KEY WORDS danazol.diglyceride.drugdispersion.drug
solubility.lipid-baseddrugdelivery.mediumchainlipid.
monoglyceride.phasediagram.triglyceride
INTRODUCTION
Due to the application of combinatorial chemistry and
high-throughput screening in drug discovery, the majority
of new drug candidates have become extremely insoluble in
water making the development of bioavailable clinical
dosage forms very challenging (1). Two-thirds of com-
pounds emerging from the drug discovery pipeline in recent
years have an aqueous solubility <100 μg/mL (0.1 mg/mL)
(2). This would classify them as insoluble or practically
insoluble according to the definition of the United States
Pharmacopeia. Although many drug candidates are cate-
gorized as poorly water-soluble, there is no limit how low
aqueous solubility could be, since approximately one-third
of newly discovered compounds have an aqueous solubility
of <10 μg/mL. Even aqueous solubility of <1 μg/mL is
increasingly more common. A lipid-based drug delivery
system, in which the drug is solubilized by lipids or lipid-like
excipients, has been recognized as an attractive approach
for increasing the bioavailability of these compounds (3–
16). Despite the abundance of poorly water-soluble drugs
and the potential benefit of lipid-based drug delivery
systems, the application of this technology has been rather
H. N. Prajapati:A. T. M. Serajuddin (*)
College of Pharmacy & Allied Health Professions, St. John’s University
8000 Utopia Parkway
Queens, New York 11439, USA
e-mail: serajuda@stjohns.edu
D. M. Dalrymple
ABITEC Corporation, 501W 1st Avenue
Columbus, Ohio 43215, USA
Pharm Res (2012) 29:285–305
DOI 10.1007/s11095-011-0541-3limited. According to Strickley (14), a total of 31 drugs,
employing 41 lipid-based products for oral administration,
were marketed in the US in 2005. However, in most of
these cases, lipids were not used to increase bioavailability
of poorly water-soluble drugs; instead, they were used to
retard drug release. In many of the products, lipids were
not even the primary excipient. Based upon a survey of
drug products available in the US in 2004, Gursoy and
Benita (15) reported that there were only four major lipid-
based products for poorly water-soluble drugs available. Of
these, two were for cyclosporine A and two for ritonavir
and sequinavir. The situation prompted Hauss (16)t oa s k
whether it is a case of implementation failing to keep up
with innovation.
According to Porter et al. (8), a rational basis for the
selection of lipid-based excipients is ‘elusive’ and the
prediction of in vivo performance of these excipients is poor.
Thus, the widespread adoption of lipid-based strategies for
enhancing drug exposure is limited. Therefore, it is not
likely that implementation is failing to keep up with
innovation, but rather the lipid-based drug delivery
technology requires further development.
To identify a few critical factors influencing the
successful development of lipid-based formulations, one
may look to the examples of Neoral® and Sandimmune®,
both marketed by Novartis, where Neoral is the reformu-
lation of Sandimmune. In these products, a poorly water-
soluble drug (cyclosporine A) was solubilized in different
mixtures of lipid, surfactant, cosurfactant and organic
solvent. In a comparative study of biopharmaceutical
properties, it was observed that Neoral dispersed in
aqueous media as extremely fine particles (<150 nm) and
gave the appearance of a clear or transluscent solution. In
contrast, Sandimmune phase separated after dilution with
water as a milky emulsion containing large oil globules
(17,18). As a result, Neoral provided better bioavailability
than Sandimmune. It was demonstrated by Kovarik et al.
(19) that the bioavailability of cyclosporine A from a 180-
mg dose of Neoral was essentially similar to that of a 300-
mg dose of Sandimmune when both were administered as
soft gelatin capsules. Of additional benefit, the individual
variation in the pharmacokinetic parameters, such as Cmax
(maximum concentration), tmax (time to reach maximum
concentration) and AUC (area under the curve), was much
lower for Neoral. When administered with a fatty meal,
Neoral did not alter the pharmacokinetics of cyclosporine A
in humans, demonstrating practically no food effect (20,21).
These advantages of the reformulated product were
attributed to its spontaneous self-microemulsification (par-
ticle or globule size <150 nm) within the GI tract. Food
generally increases the bioavailability of poorly soluble
drugs through increased bile secretion and prolonged
gastric retention time. It is possible that the formation of
a microemulsion maximized the absorption of the drug,
leaving no room for further improvement in the presence of
food. Such a lack of food effect in humans was also
observed for other self-emulsifying lipid-based formulations
(22). Consistency of drug bioavailability, whether in the fed
or fasted state, is an important consideration for clinical
efficacy and commercial success of drug products. That is
to say, elimination of the food effect may be an attainable
goal using lipid-based formulations. For this purpose, the
active pharmaceutical ingredient must first dissolve in the
carrier, and then after oral administration, finely disperse
within the fluids of the gastrointestinal tract before it is
adequately absorbed.
There are numerous lipids consisting of triglycerides of
fatty acids commercially available to formulators as
excipients for lipid-based drug delivery systems. Many
synthetic lipids are also available in which the glycerol
backbone has been replaced by propylene glycol and/or
polyethylene glycols. Additionally, the degree of esterifica-
tion of the fatty acid moiety may vary, forming mono-, di-
and tri-glyceride forms as well as different ester forms of
propylene glycol and polyethylene glycols. The fatty acids
are not necessarily long chain (C14–C20); they can be
medium chain (C6–C12), short chain, unsaturated or
branched. Due to these differences in chemical nature,
there are numerous lipids or lipid-like excipients available
commercially, all of which are colloquially called ‘lipids’ in
the pharmaceutical field. Indeed, Cannon and Long (23)
included the following categories of excipients as lipids for
the purpose of developing oral lipid-based formulations:
long-chain triglycerides, medium-chain triglycerides, pro-
pylene glycol esters, fatty acids, monoglycerides, diglycer-
ides, and lipid mixtures. Due to such chemical differences,
the physical properties of ‘lipids’ also differ. They are
available as liquids, pastes, solids or combinations of these.
If solid, they could be amorphous and/or crystalline.
Strictly speaking, lipids are triglycerides of long chain fatty
acids, and some purists are reluctant to call medium-chain
glycerides as well as mono- and di-glycerides to be lipids.
Irrespective of whether they are strictly lipids or not, all
lipids and lipid-like excipients used in the development of
lipid-based formulations require careful characterization. In
agreement with Cannon and Long (23), we will also
consider mono-, di- and tri-glycerides of medium-chain
fatty acids as ‘lipids’ in the present investigation, the
primary objective of various studies performed being the
comparative evaluation of these three excipients for their
suitability in the development of pharmaceutical dosage
forms.
Pouton (24,25) proposed a classification system for
various lipid-based drug delivery systems according to their
general composition and ability to disperse in aqueous
media (as fine particles usually <250 nm). To date, no
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dosage forms has been reported in the literature. A cursory
look at the composition of marketed lipid-based drug
products reveals that most of the formulations are rather
complex. In addition to lipids, surfactants, co-surfactants,
etc., many of these products contain alcohol and/or organic
solvents, apparently to enhance drug solubility beyond what
could be achieved by using lipids alone. Many of these
products appear to be the result of trial-and-error experi-
ments. There are no reports on how the individual
components of a formulation are selected.
To develop a rational basis for the selection of lipid-
based excipients, we have initiated a series of studies in
which the physicochemical and biopharmaceutical proper-
ties of various lipids are compared. In this paper, results of
the combinations of mono-, di- and triglycerides of medium
chain fatty acids with a common surfactant and water are
presented. The physical effect of combining multiple
excipients was investigated through the use of phase
diagrams. The particle sizes from various regions of these
phase diagrams were measured to determine emulsification
efficiency of the different lipids employed. The viscosity of
any gel phase formed was also determined. Phase diagrams
have been used for the development of lipid-based
formulations by several investigators in the past. However,
many of those phase diagrams are partial in nature. Several
investigators used phase diagrams to identify regions of
specific lipid/surfactant mixtures giving oil-in-water micro-
emulsions, or nanoemulsions, upon dilution with water (26–
30). Shafiq et al. (31) used oil/surfactant/water phase
diagrams to determine oil-in-water microemulsion regions,
while Kang et al. (32) identified regions of both micro-
emulsions and coarse emulsions. On the other hand,
Constantinides and Scalart (33) used phase diagrams to
identify water-in-oil microemulsions. While these studies
established the importance of phase diagrams as a tool for
developing lipid-based drug delivery systems, complete
identification and characterization of all the different
phases formed are lacking. Ping et al. (34) identified various
phases in lipid/surfactant/water blends. However, only one
lipid was used in the study as the primary focus of the
researchers was to determine the effect of surfactant
mixtures and not the lipid. In addition to the formation of
oil-in-water and water-in-oil microemulsions, lipid/surfac-
tant mixtures form gels or liquid crystalline phases upon
dilution with water (35,36). The formation of a gel is more
predominant when the surfactant concentration is relatively
high (>50%). However, there are only limited reports on
characterization of the gel phase and especially on its
significance in the development of oral dosage forms. In the
present study, the multiple phases formed in various regions
of the phase diagrams, including gel phases, were evaluat-
ed. Further, the solubility of a model drug, danazol, in
different drug/surfactant mixtures was determined and the
rates of drug dispersion from systems containing individual
lipids as well as lipid/lipid mixtures were compared.
MATERIALS AND METHODS
Materials
Lipids (mono-, di- and triglycerides), surfactant (PEG-35
castor oil) and drug used (danazol), along with their trade
names, suppliers, chemical structures and compositions, are
listed in Table I. It should be noted that the lipids studied
do not exist as pure species, but are mixtures of glycerides,
with differing degrees of esterification and different fatty
acid compositions. However, only the chemical structure of
the predominant component of each excipient is given in
the table. The dicaprylate was specifically prepared by
ABITEC Corporation for the present study and is not
commercially available. Distilled water was used for all
experiments as necessary. All other reagents used were of
analytical grade or better.
Construction of Phase Diagrams
Phase diagrams were constructed following the general
procedure outlined by Li et al.( 34). Mixtures (4 g each) of
lipid/surfactant, in the following ratios, were prepared in
separate 100-mL volumetric flasks: 1:9, 2:8, 3:7, 4:6, 5:5,
6:4, 7:3, 8:2, 9:1. Water was then added to each flask at 5%
w/w, intervals. In certain phase diagrams, two lipids (fixed
ratios) were used instead of a single lipid to create the phase
diagram (a pseudoternary phase diagram). In such cases, the
weight of lipid represented the total weight of both lipids.
The phase boundaries were established by visual observation
after equilibration (shaken 15 min in a 25°C water bath in
the case of low viscosity, and shaken 30 min in a 25°C water
bath in the case of a gel). Depending upon the components
used, four different phases were observed in the phase
diagrams: (1) a clear liquid region that included clear or
translucent solutions; (2) cloudy liquids apparently consisting
of coarse emulsions;( 3 )aviscous gel; or (4) a phase-separated
mixture where the lipid separated from the aqueous phase to
form a separate layer. Selected mixtures were analyzed for
particle size and viscosity. To determine the effect of drug
upon the phase diagrams, the clear region of the specific
phase diagram prepared with glyceryl dicaprylate (as lipid)
was reconstructed in the presence of danazol (2% w/w).
Evaluation of Shake Time
After each addition of water during the determination of
phase diagrams, the mixture was shaken on a wrist-action
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Pittsburgh, PA, USA) at the highest speed setting for
15 min (at 25°C, water bath). If the mixture was viscous
and appeared to form a gel after the addition of water,
shaking was continued for 30 min (25°C, water bath).
These experimental conditions were established based upon
preliminary experiments. When no change in visual
appearance for both clear and cloudy liquid regions was
observed, the shake time was set at 15 min. In the case
of gel formation, non-uniformity in the mixtures was
observed following mixing for 15 min. Therefore,
shaking was continued for 30 min, when a uniform gel
was observed. In some preliminary experiments, flasks
were shaken overnight, with no observable difference in
appearance or phase boundaries compared to the
developed procedure.
Particle Size Determination
A DelsaNano C particle size analyzer (Beckman Coulter
Inc., Brea, CA) was used to measure the particle size of
selected lipid/surfactant mixtures at ca. 70%, 80%, 90%
and 99% (w/w) water content. Approximately 2–3m Lo f
sample was added to a disposable plastic cuvette (Beckman
Coulter disposable cell, Beckman Coulter Inc., Brea, CA)
for the particle size determination at every data point using
the dynamic light scattering technique at 25°C. The sample
was placed back into the equilibrating flask after each
analysis. As mentioned earlier, the flask was shaken (15 min)
after each aliquot of water was added. Before the
determination of particle size, the flask was equilibrated
for 10 min. The shaking was resumed only after returning
the sample to the flask, followed by addition of more water.
Table I Chemical Name, Trade Name, Structure and Composition of Lipids, Surfactant and Drug
Generic name  Trade name/Manufacturer  Primary Component Structure  Composition 
Glycerol 
monocaprylocaprate 
Capmul MCM 
ABITEC Corp. 
Columbus, OH, USA 
Medium chain length 
mono (60%) and 
diglyceride (35%) 
consisting of 83% w/w 
caprylic acid (C8) and 17% 
w/w capric acid (C10). 
HLB  4.7 
Glycerol dicaprylate  No trade name 
ABITEC Corp. 
Columbus, OH, USA 
Medium chain diglyceride 
(83%) consisting of 75%-
85% caprylic acid (C8). 
HLB  3.1 
Glycerol tricaprylate  Captex 8000 
ABITEC Corp. 
Columbus, OH, USA 
Medium chain triglyceride 
consisting of 99% caprylic 
acid (C8). 
HLB  0 
Caprylic/capric 
triglyceride 
Captex 355 
ABITEC Corp. 
Columbus, OH, USA 
Medium chain triglyceride 
consisting of mixture of 
caprylic acid (C8) and 
capric acid (C10) at 55:45 
ratio. 
HLB 0
PEG-35 castor oil  Cremophor EL 
BASF 
Tarrytown, NY, USA 
The main component 
(83%) is polyethylene 
glycol ester of ricinoleic 
acid 
 HLB 13 
Danazol Various   
Donated by a major generic 
pharmaceutical company, USA 
288 Prajapati, Dalrymple and SerajuddinTo ascertain the effect of equilibration time on particle size,
the particle size measurements of selected samples were
performed at 15, 30, 60 and 120 min. To determine the
effect of the presence of dilute acid or pharmaceutical API
on particle size, the particle sizes of several lipid/surfactant
mixtures, with and without drug, were determined after a
250-fold dilution (1 g of sample solution added to 250 mL
water or 250 mL of 0.01N HCl), where the temperature of
diluents was maintained at 37°C to mimic the gastrointes-
tinal environment.
Viscosity Measurement
The viscosities of selected gel regions were determined
u s i n gaB r o o k f i e l dR V D VI I IU l t r aC P( B r o o k f i e l d
Engineering Laboratories, Inc. Middleboro, MA, USA)
viscometer equipped with a CPE-52 cone (150 rpm). Fresh
samples with appropriate lipid, surfactant and water
contents were prepared specifically for viscosity measure-
ments. Typically, lipid/surfactant mixtures at three different
ratios (5:5, 4:6 and 2:8) were prepared, 20% (w/w) water
added, and the sample equilibrated at 25°C using a wrist
action shaker. After equilibration, a sample (~ 0.5 mL) was
taken and the viscosity determined (25°C).
Solubility Studies
Danazol, a neutral compound with an aqueous solubility
of 0.59 μg/mL and log P value of 4.53 (37), was selected
as the model drug to compare different lipids and lipid/
surfactant mixtures for drug solubility. An excess amount
of drug was added to individual lipids, the surfactant or
the lipid/surfactant mixtures. The mixtures were vor-
texed to disperse suspended drug in the solvents, and the
suspensions were then shaken using a wrist-action shaker
at maximum shaking speed (Burrell Wrist Action Shaker,
Burrell Scientific, Pittsburgh, PA, USA) for 24 h at 25°C.
Aliquots were filtered (0.45 μm polypropylene filter),
diluted and assayed for drug content by HPLC (reverse
phase C18 150 x 4.6 mm x 3.5 μm against acetonitrile/
H2O (65:35) @ 0.5 mL/min, λ=280). Each solubility
determination was conducted in duplicate. It was determined
bycontinuingvarioussolubilityexperimentsforaperiodupto
7 day that an equilibration was achieved in 24 h.
Dispersion Test
As the preconcentrates containing drugs dissolved in lipid/
surfactant mixtures are expected to disperse in the
gastrointestinal tract upon oral administration, the disper-
sion test was performed for two different lipid/surfactant
ratios (1:1 and 3:7) with drug (ca. 80% of equilibrium
solubility). Similar lipid/surfactant mixtures without the
drug served as controls. The dispersion test was performed
using USP apparatus II (paddle method, 37°C, 250 mL of
0.01 N HCL, 50 rpm) with model drug. Approximately 1 g
of preconcentrate was filled into a hard gelatin capsule (00
size) and the same procedure repeated for the control
(without drug). Aliquots from dispersion vessels, 3 mL each,
were withdrawn at 10, 15, 30, 60 and 120 min time points
for particle size analysis. The drug present in the aliquots
was analyzed after appropriate dilution with the mobile
phase using the HPLC method described earlier. The
samples collected from similar dispersion tests of the control
were also analyzed by HPLC to determine if the gelatin
capsule interfered with the analysis. All experiments were
carried out in triplicate. The aliquots were filtered
(0.45 μm) before analyzing for particle size and drug
concentration. However, when it was suspected that the
particle size might be larger than 0.45 μm, samples were
analyzed with and without filtration to investigate the effect
of filtration on the drug concentration. When any precip-
itation of the drug was observed, the aliquots were
centrifuged and the supernatant liquids analyzed for drug
concentration.
RESULTS
Phase Diagrams with Individual Lipids
As the primary objective of this study was to compare
different medium chain glycerides relevant to dosage form
development, all phase diagrams were constructed using a
common surfactant, PEG-35 castor oil (Cremophor EL).
Since the lipids and surfactant were nonionic in nature and
preliminary studies showed that there was no effect of a
change in pH on the phase diagrams, distilled water was
used as the aqueous medium. A preliminary experiment
showed that there was no change in phase diagram if
0.01 M HCl was used as the dilution medium instead of
water. The lipid/surfactant/water phase diagrams of four
medium chain lipids are shown in Fig. 1. A description of
these phase diagrams follows.
Monoglyceride/Surfactant/Water Phase Diagram
Presented in Fig. 1a is the phase diagram of a
monoglyceride/surfactant/water system, where glycerol
monocaprylocaprate (Capmul MCM EP; ABITEC) and
PEG-35 castor oil (Cremophor EL; BASF) were used as
lipid and surfactant, respectively. Since Capmul MCM
used in this phase diagram contains a mixure of
monoglyceride (60%) and diglyceride (35%) as indicated
in Table I, it is indeed a psuedoternary phase diagram.
Phase boundaries were first identified by visual observa-
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determined in the region of higher water content (>70%
w/w). If a gel phase was observed, the viscosity was
measured. It is evident in Fig. 1a that a clear liquid
solution was observed at all compositions of lipid/
surfactant containing up to 15% water. As discussed later
under DISCUSSION, the clear region represent water-in-
oil (w/o) microemulsion at low water content and oil-in-
water (o/w) microemulsion at high water content. Upon
further dilution with water, this clear region turned to a
milky-white emulsion when the lipid comprised 60% or
more of the lipid/surfactant blend. In contrast, the
solutions remained clear throughout aqueous dilution up
to 90% when the initial lipid content was 20% or less. At
the intermediate lipid content of 30 and 50%, the
solutions remained clear up to 65% dilution with water;
after which, a milky white emulsion resulted. Furthermore,
when the initial lipid content was in the middle of this range
(40%), the clear solution transformed into a gel at water
concentrations between 45 and 60%. If the mixtures turned
milky-white, the term “emulsion” was used, while the term
“clear” was used for both transparent and translucent
solutions.
T h ep a r t i c l es i z ea n a l y s i sw a sp e r f o r m e do n l yo n
mixtures deemed to be relevant to the development of oral
dosage forms where the addition of water to the lipid/
surfactant preconcentrate produced a microemulsion or an
emulsion (see Table II under the subtitle Glycerol mono-
caprylocaprate). The mixtures of lipid/surfactant with
ratios from 9:1 to 3:7 gave emulsions upon dilution with
water (≥ 70%). Although the particle sizes of these mixtures
decreased with increasing water content (70 to 99%), the
particle sizes were nonetheless large (1 to 7 μm at 70% water
and 0.3 to 2 μm at 99% water). As will be discussed later in
thispaper, we calledthe solutions“microemulsions” whenthe
average particle size was found to be less than 200 nm
(0.2 μm). It was apparent that glycerol monocaprylocaprate
formed microemulsion only at high surfactant concentrations
(>80%, giving particle sizes of 13 to 30 nm). For milky
emulsions formed upon dilution, the particle size increased
Water
Water
Water
Water
PEG-35 castor oil
(Cremophor EL)
PEG-35 castor oil
(Cremophor EL)
PEG-35 castor oil
(Cremophor EL)
PEG-35 castor oil
(Cremophor EL)
Glycerol monocaprylocaprate
(Capmul MCM EP)
Glycerol
Glycerol
dicaprylate
tricaprylate
(Captex 8000)
Caprylic/capric
triglyceride
(Captex 355)
ab
cd
Fig. 1 Phase diagrams of (a) glycerol monocaprylocaprate, (b) glycerol dicaprylate, (c) glycerol tricaprylate and (d) caprylic/capric triglycerides in
combination with PEG-35 castor oil and water. ME in the figure indicates microemulsion.
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was observed in solutions with an initial lipid content of 20%
or less upon dilution with water. These results indicated that
emulsions were thermodynamically unstable, whereas, the
microemulsions at relatively higher surfactant concentrations
were thermodynamically stable.
Diglyceride/Surfactant/Water Phase Diagram
Presented in Fig. 1b is the phase diagram of a medium
chain diglyceride (glyceryl dicaprylate), PEG-35 castor oil
(Cremophor EL) and water. Clear regions representing
water-in-oil (w/o) microemulsion were observed with all
lipid/surfactant blends containing up to 20% water except
when the initial lipid content was greater than 80%. When
lipid/surfactant mixtures with an initial diglyceride content of
70% or less were further diluted with water (25 to 60%), they
transitioned to a gel phase. Upon still further dilution, this gel
phase transitioned into a microemulsion or emulsion (o/w).
The particle size data for mixtures diluted with water ranging
from 70 to 99% are given in Table II under the subheading
Glycerol dicaprylate. Microemulsions (<100 nm) formed
when the initial lipid content was 50% or less, and emulsions
formed at higher lipid/surfactant ratios (≥70% lipid). At
90% initial lipid concentration, the particle size was in the
micron range (2 to 3 μm) upon dilution with water (≥ 99%).
There was no change in particle size with respect to time
when the clear solutions were left standing. In the case of
milky emulsions, the droplet size increased with time, again
indicating that the solutions were thermodynamically stable
and the coarse emulsions were not.
Triglyceride/Surfactant/Water Phase Diagrams
Figure 1c and d represent the phase diagrams of two different
triglycerides in combination with PEG-35 castor oil and
water. The triglycerides used in these figures were glycerol
tricaprylate (Captex 8000) and caprylic/capric triglycerides
(Captex 355), the major difference between the two being
Captex 8000 was prepared from caprylic acid (99%) while
Captex 355 was prepared from caprylic/capric acid (55:45).
Phase diagrams of the two triglycerides were qualitatively
similar, although the clear region representing o/w micro-
emulsion(startingat60%water)appearedtobeslightlylarger
for Captex 8000 than Captex 355. It should, however be
noted, that Captex 355 is slightly more hydrophobic than
Captex 8000 because of the higher capric acid (C10)c o n t e n t
but this difference may not be significant. Furthermore, the
gel phase regions of the triglycerides in Fig. 1ca n ddw e r e
larger than that of the diglyceride in Fig. 1b.
The particle sizes within the emulsion regions of Fig. 1c
and d were less than 0.5 μm( ≥ 80% water). The particle
sizes when using Captex 355 at the lipid/surfactant ratio of
9:1 were the exception, ranging from 1.7 to 3.6 μm. It is also
apparent from Table II that the particle size decreased with
increasingwatercontent(≥70%).Microemulsions(<200nm)
formed upon dilution with water (99% w/w) when the initial
lipid content was less than 50%. The biologically significant
conclusion is that medium chain triglycerides may form
microemulsions at very dilute concentrations (1 to 100
dilution).
To further illustrate the effect of dilution on particle size, a
graphical representation of particle sizes of mono-, di- and
triglycerides with surfactant at different ratios (7:3, 1:1 and
3:7) is given in Fig. 2. This is the dilution of 1 g of a lipid/
surfactant mixture with 99 g of water and could be a typical
situation in the gastrointestinal tract after ingestion of a lipid-
based formulation. The graph shows that the particle size
increased in the following order: diglyceride<triglyceride<
monoglyceride. In all cases, the diglyceride provided a
microemulsion with a particle size of ~200 nm or less,
whereas, the particle sizes for mono- and triglycerides were
somewhat larger.
As can be seen in Fig. 1, the triglycerides gave a larger
gel phase region compared to the mono- or diglycerides
(triglyceride>diglyceride>>monoglyceride). The clear re-
gion decreased in the order of monoglyceride>diglyceride
>triglyceride. However, if we just compare the clear region
Table II Particle Size (nm) with Dilution with Water at Different Lipid:
Surfactant Ratios. (n=2)
% Water Lipid : Surfactant ratio
9:1 7:3 1:1 3:7 2:8 1:9
Glycerol monocaprylocaprate (Capmul MCM EP)
70 6559 6226 1287 3093 30 15
80 6599 3410 1421 1715 24 12
90 2427 2582 705 994 22 14
99 1960 819 383 284 15 13
Glycerol dicaprylate
70 2788 683 106 54 90 35
80 2007 494 58 35 63 14
90 1844 419 45 29 21 14
99 1903 262 41 29 21 16
Glycerol tricaprylate (Captex 8000)
70 474 490 414 480 647 293
80 260 428 213 216 230 43
90 366 347 134 118 95 40
99 368 262 94 72 46 23
Caprylic/capric triglyceride (Captex 355 EP/NF)
70 1730 770 1296 632 826 103
80 1756 469 634 379 636 60
90 1890 358 388 274 393 39
99 3582 269 178 163 149 20
Lipid/Surfactant/Water Phase Diagram 291corresponding to the formation of a microemulsion, the
diglyceride provided the largest area.
Effect of the Presence of Drug on Phase Diagrams
Since lipids are formulated with drugs, it was of interest to
investigate the effect of the presence of a drug on the phase
diagram. This was determined using the clear oil-in-water
microemulsion phase of the glycerol dicaprylate/PEG-35
castor oil system (Fig. 3). For this diglyceride/surfactant
mixture, no significant difference was observed for the
microemulsion produced upon dilution with water in the
presence of danazol (2% w/w). The effect of the presence of
drug could not be determined on emulsion and gel phases,
as it was not possible to ascertain whether the drug
remained in solution or not.
Effect of Monoglyceride/Diglyceride Combination
As disclosed in Table I, the mono- and diglycerides used in
the present investigation were primarily mixtures with
varying ratios of mono- and diesters. Thus, the medium
chain monoglyceride (Capmul MCM EP) contained 60%
monoglyceride and 35% diglyceride, whereas, the diglyc-
eride used contained ~17% monoglyceride and 83%
diglyceride. As shown in Fig. 1a and b, as well as in
Table II, the difference in composition of the monoglycer-
ide and the diglyceride had a major influence on the phase
diagrams generated. While the monoglyceride (60% actual
monoglyceride content) produced only a minimal gel phase
region, it had a larger emulsion region with larger particle
sizes. In contrast, the dicaprylate (17% actual monoglycer-
ide content) gave a larger gel phase region. The micro-
emulsion region in its phase diagram was larger and the
particle size upon dilution with water was smaller
(Table II). Therefore, it was of interest to investigate the
effect of mixing the monoglyceride and the diglyceride to
generate a psuedoternary phase diagram. The phase
diagram of Capmul MCM EP and glycerol dicaprylate
(1:1) in combination with surfactant and water is given
(Fig. 4) along with the particle size analysis (Table III). This
phase diagram was constructed in the same way as those
given in Fig. 1, except that two lipids (thus the term
‘pseudo’) were used instead of one. The phase diagram
from the combination of mono- and diglycerides (Fig. 4)
was significantly different than those of the monoglyceride
(Fig. 1a) or diglyceride (Fig. 1b) alone. The area of the
emulsion phase of Fig. 1a was reduced and the area of the
gel phase of Fig. 1b was eliminated. Furthermore, the
particle size, after dilution with water (70 to 99%), was
much smaller than with monoglyceride alone and compa-
rable to that of the diglyceride alone. The primary
Fig. 3 Ternary phase diagram of glycerol dicaprylate with PEG-35 castor oil and water indicating clear region (microemulsion, ME) (a) without drug and
(b) with drug (2% w/w danazol).
Fig. 2 Comparison of particle size of all four lipids at different lipid/
surfactant ratios at 99% water.
292 Prajapati, Dalrymple and Serajuddinadvantage observed in the phase diagrams of Fig. 4 over
Fig. 1b (diglyceride alone) was that the gel phase was not
formed. This could be significant for the rate of absorption
and bioavailability in oral drug delivery systems as a gel
may trap the drug, thereby delay or impede its release.
Based upon the compositions of lipids given in Table I,
the concentrations of monoglyceride and diglyceride in a
1:1 mixture of Capmul MCM and glycerol dicaprylate
were ca. 40 and 60%, respectively. Thus, in the three lipid
systems used in the present study containing both mono-
and diglycerides (1, Capmul MCM, 2, Capmul MCM/
glycerol dicaprylate, 1:1; and 3, glycerol dicaprylate), the
concentration of the monoglyceride was ca. 60, 40 and 17%
and the concentration of diglyceride was ca. 35, 60 and
83%, respectively. From the major differences observed in
the phase diagrams (Figs. 1a, 4 and 1b, respectively) and
the particle size data for the three systems, it was apparent
that lipids used in a drug delivery system may be optimized,
according to formulation requirements, by adjusting their
composition through admixture.
Effects of Monoglyceride/Triglyceride Combinations
Figure 5a, b and c represent psuedoternary phase diagrams
where the lipid phase was 1:3, 1:1 and 3:1 mixtures of the
monoglyceride (Capmul MCM) to triglyceride (Captex
355), respectively. The particle size analyses corresponding
to these figures are given in Table IV. Comparing Fig. 5a
to b, the area of the clear liquid phase progressively
increased, while the gel phase progressively decreased.
Indeed, the area of microemulsion for the combination
Capmul MCM/Captex 355 (1:1) was very large. No
further enlargement in the clear region was observed when
the ratio of monoglyceride/triglyceride was increased to
3:1. Rather, the emulsion region remained large, and as
can be seen (Fig. 5c), a phase separation of lipid was
observed upon dilution with water (>75% w/w and initial
lipid concentration≥80%). For the microemulsion phase,
the particle size was smaller in the case of the combination
compared to the individual monoglyceride and triglyceride.
Thus, the mixing of monoglyceride with triglyceride had a
major impact in reducing gel formation and promoting
microemulsion formation. These effects are similar to those
observed for mixtures of monoglyceride and diglyceride. It
is observed in Table IV that the particle size could not be
determined at 9:1 and 7:3 lipid/surfactant ratios. Similarly,
the particle size in Table III could not be determined at the
Table III Droplet Size (nm) with Dilution with Water for Mixture of
Lipids: Surfactant at Different Ratios. (n=2)
% Water Lipid : Surfactant ratio
9:1 7:3 1:1 3:7 2:8 1:9
Glycerol monocaprylocaprate : Glycerol dicaprylate (1:1)
70 ND 1029 1079 150 82 80
80 ND 1063 442 22 18 17
90 ND 870 252 18 16 17
99 ND 50 78 20 16 16
ND Not determined due to phase separation of lipid
Fig. 4 Phase diagram of mixtures of glycerol monocaprylocaprate and glycerol dicaprylate (1:1) with PEG-35 castor oil and water. PS and ME in the figure
indicate phase separation and microemulsion, respectively.
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(Cremophor EL)
Mixture of glycerol
monocaprylocaprate
(Capmul MCM EP) and
caprylic/capric
triglyceride (Captex 355)
at 1:3 ratio
PEG-35 Castor oil
(Cremophor EL)
Water
Water
Water
Mixture of glycerol
monocaprylocaprate
(Capmul MCM EP) and
caprylic/capric
triglyceride (Captex 355)
at 1:1 ratio
PEG-35 Castor oil
(Cremophor EL)
Mixture of glycerol
monocaprylocaprate
(Capmul MCM EP) and
caprylic/capric
triglyceride (Captex 355)
at 3:1 ratio
Fig. 5 Phase diagram of mixtures
of (a) glycerol monocaprylocaprate
and caprylic/capric triglycerides
(1:3), (b) glycerol monocaprylo-
caprate and caprylic/capric triglyc-
eride (1:1), and (c) glycerol
monocaprylocaprate and caprylic/
capric triglycerides (3:1), in combi-
nation with water and PEG-35
castor oil. PS and ME in the figure
indicate phase separation and
microemulsion, respectively.
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content was due to phase separation of lipid as shown
earlier in Figs. 5c and 4. It appears that there was not
enough surfactant available to emulsify lipids at high
dilution with aqueous media since much of the surfactant
was apparently below the critical micelle concentration.
Effect of Low pH and Presence of Drug on Particle
Size
Tables II, III and IV give the particle size data for drug-free
lipid/surfactant mixtures up to the maximum 1:99 dilution
with water (99% w/w). It is, however, recognized that after
oral administration, a lipid-based delivery system would be
diluted with an acidic gastric fluid rather than pure water.
The gastrointestinal (GI) fluid volume according to the
biopharmaceutical classification system is considered to be
250 mL, and the temperature in the GI environment is 37°
C.Therefore, particle sizes of selected lipid/surfactant
systems, with and without drug (2% w/w danazol), were
determined after dilution with water (1:250) or dilute acid
(0.01 M HCl) at 37°C. The results are presented in
Table V. No significant effects from dilute acid (0.01 M
HCl) or the presence of drug (danazol, 2%) were observed.
Viscosity of Gels
The formation of a gel phase was observed in some of the
phase diagrams for certain lipid/surfactant ratios with
water concentrations from ca.2 0 –60% (glycerol dicapry-
late, glycerol tricaprylate (Captex 8000) and caprylic/capric
triglycerides (Captex 355)). The viscosities of various gel
phases were measured and the results given in Table VI at
25°C. The gels were soft with low viscosity and, in general,
the viscosity increased with increasing water concentration
and then decreased upon further addition of water until the
gel transitioned into a microemulsion or emulsion.
The addition of monoglyceride to di- and triglycerides not
only decreased the gel phase, as previously mentioned, it also
decreased the viscosity of any gel formed. The effect of the
addition of monoglyceride (Capmul MCM EP) to a triglyc-
eride (Captex355)at a 1:3 ratio is shown graphically inFig.6.
The effect of the addition of monoglyceride to triglyceride
appeared to be a reduction in the viscosity of the gel formed
until the gel almost or completely disappeared.
Solubility
The solubilities of danazol in different lipids individually
and in mixtures with each other or with the surfactant
(Cremophor EL) are given in Table VII. Danazol is a
neutral compound with no ionizable functional group.
Considering that its solubility is only 0.59 μg/mL in
aqueous media, a major increase in solubility with lipids
and the surfactant was observed. Among the lipids, both
monoglyceride and diglyceride provided greater solubility
(19 to 21 mg/g) than the triglycerides (7 mg/g). These
results indicate the advantage of using the partially
esterified medium chain glycerides (mono- and diglycerides)
over the fully esterified glyceride (triglyceride). The
solubility of danazol in Cremophor EL is higher than
those in any of the lipids used (32 mg/g). Therefore, in
addition to hydrophobic fatty acid chains, the presence of
polar hydroxyl (mono- and diglycerides) and ethylene
oxide (Cremophor EL) groups are also important in
solubilizing a poorly soluble drug like danazol.
When the lipids were mixed with each other or with the
surfactants, the solubility changed in proportion to the
solubility in the individual components. That is, the
solubility behaved linearly. For example, the solubility of
danazol in Capmul MCM and Cremophor EL are 21 and
32 mg/mL, respectively. When these two components were
mixed (1:1), the solubility of danzaol was 26 mg/mL, which
is essentially the average of its solubility in the individual
components. The theoretical solubilty of danazol in
different mixtures is given in Table VII. These data
indicate that the experimentally determined solubility
values for lipid/surfactant mixtures are similar to those
calculated theoretically. When two components were mixed
at different ratios, no significant synergistic increase (or
decrease) in solubility was observed. Similar effects were
noted previously by other investigators (38).
Table IV Particle Size (nm) with Dilution with Water for Mixture of
Lipids: Surfactant at Different Ratios. (n=2)
% Water Lipid : Surfactant ratio
9:1 7:3 1:1 3:7 2:8 1:9
Glycerol monocaprylocaprate : Caprylic/capric triglyceride (1:3)
70 2532 9993 699 86 93 91
80 987 2688 344 31 17 20
90 1083 1063 261 20 18 16
99 163 769 119 22 19 17
Glycerol monocaprylocaprate: Caprylic/capric triglyceride (1:1)
70 3185 113 47 27 18 24
80 5303 349 21 18 14 33
90 867 533 21 16 18 16
99 434 40 24 19 18 17
Glycerol monocaprylocaprate: Caprylic/capric triglyceride (3:1)
70 ND ND 2110 50 32 15
80 ND ND 2314 20 14 13
90 ND ND 880 16 14 12
99 ND ND 164 18 18 15
ND Not determined due to phase separation of lipid
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The primary components of lipid-based pharmaceutical
dosage forms are lipid, surfactant and drug. Such a mixture
or preconcentrate is expected to disperse after oral
ingestion as an emulsion or microemulsion in the gastroin-
testinal tract. It is also expected that the dissolved drug
would not precipitate upon dilution. A dispersion test was
performed for various lipid/surfactant mixtures, with and
without dissolved danazol. This was to determine 1) how
easily the preconcentrates emulsify in aqueous media, 2)
what are the particle sizes of any emulsions formed, 3) what
is the effect of the presence of drug on emulsification or
particle size, and 4) if any precipitation of drug is observed
(39). The test was conducted in 250 mL of 0.01 N HCL
(pH 2) at 37°C by using the relatively low agitation of 50
rpm to mimic the physiological condition in the human
stomach.
Figure 7a and b show the results of dispersion tests with
individual lipids (lipid/surfactant 1:1 and 3:7). In these
figures, the concentration of drug dispersed in water is
plotted as a function of time. Although the capsule shell
quickly disintegrated (< 5 min), an initial, slow dissolution
rate (up to 15 min) was observed, except in the case of the
monoglyceride (Capmul MCM). It has been shown in
Fig. 1 that gels formed when water was added to lipid/
surfactant mixtures of diglyceride and triglyceride. Thus,
the lag time in the dispersions given in Fig. 7a and b may
have been due to gel formation. The gel disappeared upon
further stirring and complete dispersion (>80%) was
observed within 30 to 60 min. Drug concentration data
shown in Fig. 7a and b are for filtered samples (0.45 μm).
The concentrations were about 5% higher when unfiltered
samples were used (data not shown). It appeared that the
lipids formed a thin layer at the surface of the dispersion
medium and adsorbed slightly at the inner surface of the
% water Lipid: Surfactant ratio
1:1 4:6 2:8
Glycerol dicaprylate
20 ND ND ND
30 77 79 91
40 89 102 105
50 62 99 64
60 ND ND ND
Glycerol tricaprylate
20 116 116 184
30 86 179 122
40 169 125 195
50 109 79 106
60 ND ND 91
Caprylic/ Capric triglyceride
20 120 77 130
30 110 114 194
40 99 107 175
50 ND 93 140
60 ND ND 106
Table VI Viscosity (cP) of Gel
with Dilution with Water at Dif-
ferent Lipid: Surfactant Ratios
ND Not determined as gel was
not formed
Table V Particle size(nm)ofEmulsion/microemulsion System in1:250 DilutionithWater and0.01N HCLat37°CwithDifferentLipid:SurfactantRatios(n=2)
Lipid/Mixture of lipids
a Surfactant
b Weight ratio 1:250 dilution
without drug in
water
1:250 dilution with
drug (19 mg/g) in
water
1:250 dilution
without drug
in 0.01 N HCL
1:250 dilution with
drug (19 mg/g)
in 0.01 N HCL
Capmul MCM Cremophor EL 1:1 297 290 293 296
3:7 236 236 231 233
Glycerol Dicaprylate Cremophor EL 1:1 47 47 46 45
3:7 22 26 22 22
Captex 8000 Cremophor EL 1:1 75 76 77 75
3:7 27 26 26 29
Captex 355 Cremophor EL 1:1 80 83 77 75
3:7 30 30 28 28
Captex 355-Capmul MCM (3:1) Cremophor EL 1:1 32 31 32 31
3:7 22 21 21 22
Captex 355-Capmul MCM (1:1) Cremophor EL 1:1 23 25 26 23
3:7 20 19 20 21
Captex 355-Capmul MCM (1:3) Cremophor EL 1:1 90 90 92 93
3:7 19 19 18 19
aCapmul MCM - Glycerol monocaprylocaprate , Captex 8000 - Glycerol tricaprylate and Captex 355 - caprylic/capric triglyceride
bCremophor EL – PEG-35 castor oil
296 Prajapati, Dalrymple and Serajuddindispersion vessels, which could lower drug concentration in
the dispersion medium. For these reasons, we considered a
dispersion to be complete if a drug concentration greater
than 80% was observed. Thus, it may be concluded from
Fig. 7a and b that, although there may be an initial lag
time, a complete dispersion of drug and lipid was obtained
from lipid/surfactant mixtures of di- and triglycerides. No
lag time for the dispersion of the monoglyceride was
observed in Fig. 7a and b. This may be explained by the
lack of gel formation in the phase diagram. However, the
dispersion of drug from the monoglyceride was incomplete,
which could be related to the formation of an emulsion
rather than a microemulsion; and in the case of the
monoglyceride/surfactant ratio of 3:7 in Fig. 7b, due to
the precipitation of drug at ≥ 45 min. In a separate study,
danazol was dissolved in the surfactant (Cremophor EL)
and the dispersion test performed; danazol started to
precipitate within 45 min. It is thus apparent that
Cremophor EL alone, or in mixtures with monoglyceride
(3:7), cannot keep the drug dispersed or solubilized in
aqueous media. No such dispersion issue was observed for
diglyceride and triglyceride. The mechanism of the precip-
itation of drug from the monoglyceride at 3:7 lipid/
surfactant ratio, and not from diglyceride and triglyceride,
was not investigated.
Figure 8a and b show the dramatic effect of the dispersion
of danazol when two lipids (mono- plus diglycerides or mono-
plus triglycerides) were combined with the lipid/surfactant
ratios of 1:1 and 3:7. It was demonstrated earlier that gel
formation in the phase diagrams may be eliminated by using
lipid mixtures (Fig. 5). In these cases, greater than 80%
danazol dispersed within 10–15 min with no observable lag
time, with the exception of the mixture of glycerol mono-
caprylocaprate (Capmul MCM) and caprylic/capric triglyc-
eride (Captex 355) at ratio at 1:3 that exhibited gel
formation at 1:1 lipid/surfactant mixture (Fig. 5a). Although
Fig. 5a shows that there was also gel formation at the 3:7
lipid-surfactant ratios, no lag time was observed for the
dispersion of the 1:3 mixture of glycerol monocaprylocaprate
(Capmul MCM) and caprylic/capric triglyceride (Captex
355) in Fig. 8b. This could be related to the viscosity of the
two systems; the 1:1 lipid/surfactant ratio gave higher
viscosity than the 3:7 lipid/surfactant ratio (data not shown).
Table VIII summarizes the particle size analyses vs. time
during the dispersion tests. The presence of drug in the
dispersed phase gave no observable difference in the
particle size. The particle size analysis during dispersion
testing confirms the earlier observations in the phase
diagrams. Emulsions with relatively large particles (~400–
500 μm) were formed when Capmul MCM alone was used
with the surfactant (lipid/surfactant 1:1), while the particle
size decreased by a factor of almost 10 (< 50 nm) when
Capmul MCM was mixed with either a diglyceride or
triglyceride (Captex 355) at 1:1 ratio. This was a major
improvement over the performance of the individual lipids.
The monoglyceride (Capmul MCM) gave particle sizes in
the range of 400 to 500 nm, while the diglyceride and
triglycerides (Captex 355 and Captex 8000) gave particle
Fig. 6 Comparison of viscosities (25°C) vs. percent water for caprylate/ capric triglyceride (Captex 355) and the mixture of caprylate/ capric triglyceride
and glycerol monocaprylocaprate at 2:8 lipid to surfactant (Cremophor EL) ratio.
Lipid/Surfactant/Water Phase Diagram 297sizes in the range of 100 to 200 nm. When the lipid ratio of
monoglyceride/triglyceride was increased from 1:1 to 3:1,
that is the percentage of monoglyceride was increased, the
particle size after dispersion increased about 10 fold (ca.
30 nm to 300 nm.) The particle size, however, remained
small (40–70 nm) at higher surfactant concentration. These
results are in agreement with the phase diagram in Fig. 5c,
which showed that the mixture of monoglyceride/triglyc-
eride (3:1) formed a microemulsion upon dilution with
water only at a high surfactant level.
DISCUSSION
Although it is desirable for the development of lipid-
based pharmaceutical dosage forms that a drug has
Lipid: Surfactant
a Solubility (mg/g) (Experimental) Solubility (mg/g) (Calculated)
Capmul MCM: Cremophor EL
1:0 21 –
7:3 26 25
1:1 26 27
4:6 30 28
3:7 29 29
0:1 32 –
Glycerol Dicaprylate : Cremophor EL
1:0 19 –
7:3 22 23
1:1 24 26
4:6 28 27
3:7 29 28
Captex 8000:Cremophor EL
1:0 7 –
7:3 16 15
1:1 19 20
3:7 25 25
Captex 355:Cremophor EL
1:0 7 –
7:3 19 15
1:1 20 20
4:6 19 22
3:7 21 25
Captex 355(3)-Capmul MCM(1): Cremophor EL
1:0 10 –
7:3 18 17
1:1 27 21
3:7 27 25
Captex 355(1)-Capmul MCM(1):Cremophor EL
1:0 16 –
7:3 21 21
6:4 21 22
1:1 23 24
4:6 23 26
3:7 34 27
Captex 355(1)-Capmul MCM(3) : Cremophor EL
1:0 21 –
1:1 29 27
3:7 34 26
Table VII Solubility of Danazol
at Different Ratios of Lipid/mixture
of Lipids and Surfactant. (n=2)
aCapmul MCM - Glycerol
monocaprylocaprate , Captex
8000 - Glycerol tricaprylate,
Captex 355 - caprylic/capric
triglyceride and Cremophor
EL – PEG-35 castor oil
298 Prajapati, Dalrymple and Serajuddinhigh solubility in the lipids used, there is no clear
consensus in the pharmaceutical literature as to what
determines the solubility of drugs in lipids. The
selection of lipids is still made by trial and error. The
medium chain lipids, however, have gained popularity
i nr e c e n ty e a r sa st h e yh a v ed e m o n s t r a t e dh i g h e rd r u g
solubilities compared to long chain lipids (40). Medium
chain lipids are liquids at room temperature; whereas,
many long chain lipids, especially partial glycerides, are
v i s c o u ss e m i s o l i d so rs o l i d sa tr o o mt e m p e r a t u r e( 11).
The results of the present investigation showed that
lipid/surfactant mixtures, which are generally used in
self-emulsifying pharmaceutical dosage forms, can exist
in different phases upon dilution with water. Since the
different phases formed may have different utility and
serve different purposes in formulations, it is essential
that we discuss these phases in more detail.
Possible Structural Changes Following Addition
of Water to Lipid/Surfactant Mixtures
The fate of different lipid/surfactant mixtures upon dilution
with water may be explained with the schematic phase
diagram in Fig. 9a. The line A to B depicts the dilution of a
Fig. 7 Cumulative % danazol present in dispersion media at (a) 1:1 ratio of lipid to surfactant (b) 3:7 ratio of lipid to surfactant (Cremophor EL).
Lipid/Surfactant/Water Phase Diagram 299lipid/surfactant (1:1) mixture with water and the line C to
D depicts the dilution of a lipid/surfactant (7:3) mixture
with water. If one follows along the line A to B, a clear
liquid is observed at low water content, which converts to a
gel upon addition of more water and then reconverts to a
clear or transluscent liquid phase upon further addition of
water. There are many reports in the literature that
analyzed microstructures of such phase transitions (41–46).
It is generally recognized that upon addition of water the
lipid/surfactant mixture successively forms a water-in-oil
(w/o) microemulsion, a bicontinuous gel phase, followed by
an oil-in-water (o/w) microemulsion. The possible struc-
tures of theses phases and the change in curvature of the
surfactant layer along the change from w/o to o/w micro-
Fig. 8 Cumulative % danazol present in dispersion media at (a) 1:1 ratio of mixture of lipids: surfactant (b) 3:7 ratio of mixture of lipids/surfactant
(Cremophor EL).
300 Prajapati, Dalrymple and Serajuddinemulsion are shown schematically in Fig. 9b. The gel is an
intermediate phase occurring at the phase inversion from a
w/o to o/w microemulsion. It may be comprised of different
structures beginning with a lamellar bilayer as shown in
Fig. 9b that may evolve into hexagonal phases in which
surfactant molecules aggregate into circular cylindrical
micelles and/or bicontinuous cubic phases. In all of these
structures, the bilayer divides the space into two interwoven
continuous networks of water and lipid/surfactant combina-
tions (41). Sagalowicz et al.( 45) reported that there may be as
many as six different self-assembled structures of hexagonal,
lamellar and cubic types in the transition from the w/o
reversed micellar or microemulsion system to an o/w micel-
lar or microemulsion system. Since a detailed investigation of
the microstructure of the gel phase has not been conducted
in the present study, we depicted the gel phase only with a
lamellar structure for the purpose of illustrating a change in
the curvature of the surfactant layer during phase transition
from w/o and o/w microemulsions (Fig. 9b).
Some of the different lipids (mono- and diglycerides) used
in the present study are surface active in nature as they have
polar functional groups as well as nonpolar hydrocarbon
chains. However, the glycerides are less hydrophilic and have
lower HLB values than Cremophor EL whose long polyeth-
ylene oxide chain makes it more hydrophilic. As shown in
Fig. 9b, when the lipid is mixed with the surfactant at a ratio
of around 1:1 (or lower), the two species may participate in
forming the bilayer and then the o/w microemulsion. This is
not the case when the lipid to surfactant ratio is higher, as
shown by line C to D in the schematic phase diagram of
Fig. 9a. The lipid/surfactant mixture converts to an
emulsion instead of a gel when the lipid/surfactant ratio is
high. The possible reason for this phenomenon is that the
concentration of the hydrophilic surfactant is not sufficient
enough to enable the formation of bilayer along with lipid.
Instead, Fig. 9c illustrates that the water is initially absorbed
into the lipid/surfactant mixture. Upon dilution, this is
followed by the formation of a biphasic emulsion system
Table VIII Particle Size at Different Time Interval of Dispersion Test of
Danazol at Different Ratios of Lipid: Surfactant and Mixture of Lipids:
Surfactant (n=3)
Time (min) Particle size (nm) ± s.d.
1:1 (Lipid: Surfactant) 3:7 (Lipid:Surafactant)
Control With drug Control With drug
Capmul MCM
a
10 434±19 424±17 420±19 430±12
15 471±17 440±19 492±12 500±15
30 517±20 486±20 556±13 557±15
60 493±12 487±16 499±12 563±16
120 506±13 522±11 496±14 565±13
Glycerol dicaprylate
10 94±4 92±5 80±5 69±3
15 104±5 107±3 80±4 68±2
30 113±2 115±2 67±5 69±1
60 114±3 119±3 69±5 56±1
120 113±2 116±1 61±2 66±3
Captex 8000
b
10 123±3 125±3 30±1 29±3
15 161±2 156±5 29±1 27±3
30 179±4 173±4 29±1 26±2
60 183±5 176±2 28±1 26±1
120 175±4 176±3 27±2 25±1
Captex 355
c
10 159±3 127±5 28±2 29±1
15 197±5 168±4 27±3 28±1
30 217±4 196±3 28±1 23±3
60 225±3 199±5 26±3 28±1
120 216±2 200±2 25±3 28±1
Capmul MCM :Glyceryl dicaprylate (1:1)
10 62±3 41±1 325±20 236±24
15 59±2 40±3 372±24 253±18
30 57±4 40±2 363±19 379±20
60 50±1 38±2 377±20 469±19
120 67±2 40±3 404±25 451±21
Capmul MCM : Captex 355 (1:3)
10 31±3 31±3 21±1 21±2
15 40±1 32±1 24±2 21±1
30 49±3 39±4 21±3 21±2
60 36±2 36±1 23±1 21±3
120 36±1 34±1 21±1 22±1
Capmul MCM : Captex 355 (1:1)
10 28±1 25±2 19±1 21±1
15 27±2 28±1 20±2 22±1
30 32±1 29±2 20±3 23±2
60 29±3 28±2 19±2 22±2
120 29±1 28±1 20±1 24±1
Capmul MCM : Captex 355 (3:1)
10 266±10 325±11 47±1 49±2
Table VIII (continued)
Time (min) Particle size (nm) ± s.d.
1:1 (Lipid: Surfactant) 3:7 (Lipid:Surafactant)
Control With drug Control With drug
15 299±9 324±7 54±2 51±1
30 291±8 426±7 69±1 67±3
60 323±7 421±5 66±2 44±3
120 287±5 320±5 60±2 40±2
aCapmul MCM - Glycerol monocaprylocaprate
bCaptex 8000 - Glycerol tricaprylate
cCaptex 355 - Caprylic/capric triglyceride
Lipid/Surfactant/Water Phase Diagram 301Fig. 9 Schematic representation
of (a) phase diagram with dilution
curve, (b) conversion from w/o
into o/w microemulsion passing
through the gel phase as shown
by line A to B in the phase
diagram, and (c) conversion from
w/o into o/w emulsion as shown
by line C to D in the phase
diagram.
302 Prajapati, Dalrymple and Serajuddinwhere the lipid aggregates at the core of the emulsion droplet
and the hydrophilic surfactant forms the outer layer.
The mechanism of the dramatic effect of combining
monoglyceride with di-or triglycerides in eliminating the gel
phase, expanding the microemulsion region, and reducing
the particle size was not elucidated in the present study. It
appears that the monoglyceride is acting as a cosurfactant
with Cremophor EL as it has an intermediate HLB value.
Further work in this area is continuing.
Pharmaceutical Application of Lipid/Surfactant/Water
Phases
A few of the possible pharmaceutically important phases of
lipid/surfactant/water systems depicted in Figs. 1, 4 and 5
are described below:
Lipid/Surfactant Mixture and Water-in-Oil Microemulsion
The clear region of either neat lipid/surfactant mixture with
no water present or the lipid/surfactant mixture with a
relatively low water content (<15%) in the phase diagrams
oftenserves as the carrierfor lipid-based drug delivery systems.
Since some of these mixtures form o/w microemulsion upon
dilution with water, they are sometimes referred to as micro-
emulsion preconcentrates. Depending on drug solubility, a
drug formulation in such mixtures results in a soft or hard
gelatin capsule or a liquid solution dosage form.
Gel
The gel phase could be a transition phase in between w/o
microemulsions and o/w microemulsions. The dispersion
experiments in the present investigation showed that
although the gel formation could initially retard dispersion
of a formulation upon dilution with water, a complete
dispersion with the formation of either a microemulsion or
an emulsion occurred in all cases within 60 min. Thus, the
gel formation may not have a major impact on the
bioavailability of an oral dosage form.
Gels per se may also be used as pharmaceutical dosage
forms because of their semisolid and viscous properties (47–
51). Gels may prolong the release of drug after oral
administration or topical application. In particular, gels
may be applied to body cavities, such as eye, nose, vagina,
etc., for increasing contact time and prolonging drug
release. There is a recent report that a gel may also be
used for periodontal anesthesia (47). Gels may be formed
within cavities in situ when formulations with lipid/
surfactant mixtures come in contact with the limited water
present in body cavities, or they may be administered as
finished products formulated by adding water. In addition
to poorly soluble drugs, the gel may also serve as a reservoir
for proteins and water-soluble drugs. There is also the
potential of the lipid/surfactant mixtures, with or without a
low level of water, administered intramuscularly for the
formation of in situ gels such as the long-acting parenteral
depot system.
Microemulsion
The clear or translucent phase (≥ 50% water) is often
referred to as the microemulsion, or more precisely, the
o/w microemulsion phase. The phase diagrams in the
present investigation were initially constructed by visual
observation of the different phases formed. Subsequent
analysis indicated that the particle size of the micro-
emulsion phase was < 200 nm. There has been a long
controversy over what constitutes a microemulsion and
whether it is an emulsion or a micelle (52,53). It is now
generally recognized as the thermodynamically stable
micellar or swollen micellar system of lipid, surfactant
and water (54). It is formed spontaneously upon addition
of water to lipid/surfactant or lipid/surfactant/cosurfac-
tant mixtures.
The phase diagrams generated in the present investiga-
tion identified various microemulsion regions produced
following dilution of lipid/surfactant mixtures with water.
They also demonstrate how the microemulsion phase may
be expanded with higher lipid content by using mixtures of
two lipids instead of using them individually. These results
should help formulators in selecting microemulsion pre-
concentrates (lipid/surfactant mixtures) for various dosage
forms.
Emulsion
When the lipid/surfactant mixtures turned cloudy upon
dilution with water, we considered them emulsions. In most
cases where the preconcentrates were diluted with water at
1:99 or 1:250 ratios and the emulsions were formed, the
particle sizes were still relatively low, usually in the
submicron range (Tables II, III and IV). Depending on
the properties of drugs, some formulators may find such a
reduction in particle size suitable for bioavailability en-
hancement. The drug concentrated in emulsion globules
may be released and available for absorption through
lipolysis within the gastrointestinal tract (55,56). Therefore,
it may not always be necessary to form a microemulsion for
bioavailability enhancement as emulsions with particle sizes
under one micron (or even higher) may be sufficient. If the
surfactant concentration is low in the emulsion phase due to
a low lipid/surfactant ratio, one should, however, be
mindful of the potential phase separation of the lipid from
aqueous media as indicated by the phase diagrams of
Figs. 4 and 5c.
Lipid/Surfactant/Water Phase Diagram 303CONCLUSION
Mixtures of lipids and surfactants are often used as solvents
or carriers for poorly water-soluble drugs. They form a
microemulsion (particle size<200 nm) or an emulsion
(particle size>200 nm) upon dilution with water or GI
fluids, if taken orally. Although it is often expected that
lipid/surfactant mixtures would produce a microemulsion
upon dilution with water, we demonstrated using mono-,
di- and triglycerides of medium chain fatty acids in
combination with a common surfactant (PEG-35 castor
oil) that the formation of microemulsion with these
glycerides is often complex. For many lipid/surfactant
mixtures, the formation of macroemulsions rather than
microemulsions was observed, making the microemulsion
phase rather small. In addition, gel or liquid crystalline
phases were produced in the cases of diglycerides and
triglycerides. The microemulsion phase could be expanded
and the gel phase practically eliminated by combining
monoglyceride with diglyceride or triglyceride at 1:1 ratios.
However, it is also recognized that the gel formation may
be desirable if the formulation is used topically or
administered to body cavities (e.g., nose). There was no
effect of the presence of a model drug, danazol, on the
phase diagram or particle size after dilution with water.
The dispersion rate of microemulsion preconcentrates
(danazol dissolved in lipid/surfactant mixture) in aqueous
media could be enhanced and the particle size of the
microemulsion or emulsion formed reduced by using
mixtures of lipids. It is hoped that this paper will provide
practical guidance to formulation scientists in selecting
appropriate medium chain glycerides for dosage form
development based on lipid-surfactant ratio, particle size,
drug solubility, dispersion of preconcentrate in aqueous
media, absence or presence of gel phase and so forth.
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